---

---

tags : Pharma    crawled time : 19:00   

save search

---

MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
MEIP | $3.38 2.11% 12K |

Health Technology

| -14.51% | O: -1.08% H: 1.9% C: 0.78%
pharma update leukemia study

---

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
SHPH | $0.4099 9.7K |

| 15.33% | O: 4.08% H: 0.0% C: -2.27%
pharma offering

---

Sun Pharma Canada Launches (PR)ABSORICA LD (isotretinoin capsules) for Treatment of Severe Acne
Published: 2023-12-04 (Crawled : 19:00) - biospace.com/
TARO | $42.305 0.15% 5.9K |

Health Technology

| 14.47% | O: 0.27% H: 0.5% C: -0.27%
pharma treatment canada acne

---

Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023
Published: 2023-10-16 (Crawled : 19:00) - biospace.com/
NVO | News | $122.675 -1.49% 2.1M |

Health Technology

| 21.92% | O: -0.84% H: 0.19% C: -0.13%
il-22 obesityweek pharma control preclinical

---

Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
Published: 2023-10-03 (Crawled : 19:00) - biospace.com/
LTRN | $5.83 -2.67% 89K |

Health Technology

| 82.62% | O: 3.35% H: 0.0% C: -11.21%
lp-184 pharma cancer publication research glioblastoma

---

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform
Published: 2023-09-11 (Crawled : 19:00) - biospace.com/
SHPH | $0.4099 9.7K |

| -41.01% | O: 0.0% H: 12.09% C: 0.72%
pharma patent platform

---

Cybin to Acquire Small Pharma Inc.
Published: 2023-08-28 (Crawled : 19:00) - biospace.com/
CYBN | $0.3668 -2.29% 910K |

n/a

| 26.53% | O: -3.37% H: 13.83% C: 8.76%
pharma acquire

---

Pharma Microbiology Testing Kits Global Market Report 2023: Rising Incidence of Infectious Diseases is one of the Prime Drivers
Published: 2023-05-24 (Crawled : 19:00) - prnewswire.com
BDX | $230.84 -0.59% 300K |

Health Technology

| -5.81% | O: -0.67% H: 0.49% C: -0.75%
ABT | News | $104.91 -0.94% 2.8M |

Health Technology

| 3.74% | O: -0.74% H: 0.25% C: -1.09%
pharma report one global prime market

---

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Published: 2023-05-12 (Crawled : 19:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21% |

Health Technology

| Email alert Add to watchlist
pharma

---

Actinium Pharma Announces Iomab-B SIERRA Trial Results Accepted for Oral Presentation at the European Hematology Association 2023 Congress (EHA)
Published: 2023-05-11 (Crawled : 19:00) - biospace.com/
ATNM | $6.93 -4.41% 220K |

Health Technology

| -8.62% | O: -0.83% H: 0.36% C: -1.43%
pharma association presentation trial results

---

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
Published: 2023-04-24 (Crawled : 19:00) - biospace.com/
NAMS | $19.76 -1.45% 150K |

n/a

| 29.19% | O: 3.83% H: 5.49% C: 5.43%
pharma hypercholesterolemia trial

---

Pharmaceutical Industry Thought Leader James Borneman Joins Bryn Pharma as Chief Operating Officer
Published: 2023-03-27 (Crawled : 19:00) - biospace.com/
SNYNF | News | $92.7 1.4K |

Health Technology

| -11.71% | O: 0.94% H: 1.0% C: 1.0%
SNY | News | $45.445 -1.44% 2.6M |

Health Technology

| -11.34% | O: 1.97% H: 0.0% C: 0.0%
pharma

---

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
Published: 2023-02-23 (Crawled : 19:00) - globenewswire.com
NVCT | $6.685 -1.11% 51K |

| -33.98% | O: -0.88% H: 2.17% C: 2.17%
nxp800 pharma presentation

---

Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®
Published: 2023-02-09 (Crawled : 19:00) - globenewswire.com
NVCT | $6.685 -1.11% 51K |

| -38.66% | O: -0.36% H: 8.47% C: 7.65%
nxp900 xtandi pharma active acquired cancer publication prostate cancer

---

Global Clinical Trial Supplies Market Report to 2027 - Featuring Almac Group, Catalent Pharma Solutions, DHL and Parexel Among Others
Published: 2023-02-09 (Crawled : 19:00) - prnewswire.com
TMO | News | $542.71 -0.83% 1.2M |

Health Technology

| -3.81% | O: -0.32% H: 0.81% C: 0.76%
pharma global report trial market

---

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236
Published: 2022-12-13 (Crawled : 19:00) - biospace.com/
VINC | $0.8899 -6.35% 390K |

| 39.71% | O: 7.22% H: 54.99% C: 48.13%
vip236 fda pharma drug application

---

Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
Published: 2022-11-29 (Crawled : 19:00) - biospace.com/
ATHA | $2.07 -1.9% 180K |

Health Technology

| -25.7% | O: -0.35% H: 3.53% C: 1.41%
pharma conference disease biomarker alzheimer’s presentation potential study fosgonimeton

---

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
Published: 2022-09-06 (Crawled : 19:00) - biospace.com/
COCP | $1.43 2.1K |

Health Technology

| -67.53% | O: 1.41% H: 0.0% C: -5.84%
pharma global conference

---

ApiJect Announces Investment by Royalty Pharma and Jefferies
Published: 2022-05-18 (Crawled : 19:00) - prnewswire.com
JEF 4 | $41.46 0.66% 390K |

Finance

| 33.13% | O: -1.71% H: 2.04% C: 0.62%
pharma

---

aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
LIFE | $1.64 3.15% 160K |

Health Technology

| -48.04% | O: 0.0% H: 5.23% C: 0.65%
atyr1923 pharma phase 3

---

Gainers vs Losers

68%

32%

Top 10 Gainers

AGBA | $1.05 162.5% 100M |

Finance

ISPC | $0.4621 116.95% 15M |

Professional, Scientific, and T...

INVO | $1.515 99.34% 4.3M |

Health Technology

BPTH | $5.62 73.46% 75M |

Health Technology

TIRX | $0.8231 69.78% 54M |

XPON | $2.63 36.27% 8.4M |

PRTG | $0.299 35.17% 120K |

Mining, Quarrying, and Oil and ...

VTNR S | $1.26 28.68% 9.1M |

Industrial Services

SWVL | $9.64 27.35% 200K |

n/a

DFLI A | $0.7726 25.52% 4.3M |

---

Your saved searches

---